Beijing Sun-Novo Pharmaceutical Co., Ltd. (688621)
Market Closed
11 Aug, 06:57
SSE SSE Primary ¥
63. 86
-0.44
-0.6843%
¥
5.02B Market Cap
- P/E Ratio
0.66% Div Yield
2.87M Volume
- Eps
¥ 64.3
Previous Close Want to track 688621 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
688621 closed today lower at ¥63.86, a decrease of -0.6843% from yesterday's close, completing a monthly increase of 17.4329% or ¥9.48. Over the past 12 months, 688621 stock gained 1.9802%.
688621 pays dividends to its shareholders, with the most recent payment made on Jun 29, 2026. The next estimated payment will be in In 10 months on Jun 29, 2027 for a total of ¥0.187.
The last earnings report, released on Oct 28, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Beijing Sun-Novo Pharmaceutical Co., Ltd. has completed 1 stock splits, with the recent split occurring on May 12, 2023.
The company's stock is traded on one exchange.
688621 Chart
People also search for
Beijing Sun-Novo Pharmaceutical Co., Ltd. (688621) FAQ
What is the stock price today?
The current price is ¥63.86.
On which exchange is it traded?
Beijing Sun-Novo Pharmaceutical Co., Ltd. is listed on SSE.
What is its stock symbol?
The ticker symbol is 688621.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.66%.
What is its market cap?
As of today, the market cap is 5.02B.
Has Beijing Sun-Novo Pharmaceutical Co., Ltd. ever had a stock split?
Beijing Sun-Novo Pharmaceutical Co., Ltd. had 1 splits and the recent split was on May 12, 2023.
Beijing Sun-Novo Pharmaceutical Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Yujing Liu CEO | SSE Exchange | CNE100005139 ISIN |
| CN Country | 1,370 Employees | 29 Jun 2026 Last Dividend | 12 May 2023 Last Split | - IPO Date |
Overview
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., founded in 2009 and headquartered in Beijing, China, is a multifaceted contract research company primarily dedicated to the pharmaceutical sector. Its operations span across comprehensive platforms for drug research and development, including new and generic drug formulations, pediatric medications, respiratory treatments, polypeptide molecular design, and genotoxic impurity detection. With a focus on both chemical and biological drugs, as well as medical devices, Beijing Sun-Novo has established itself as a key player in advancing pharmaceutical research and development within China.
Products and Services
- External Preparation Platform: Focuses on the R&D of new and generic drugs for skin, offering solutions for topical pharmaceutical applications.
- Pediatric Research Platforms: Includes centers and platforms dedicated to children's clinical data bridging, pediatric drug R&D, and delivery dosage R&D, addressing the unique needs of pediatric medication.
- Respiratory and Topical Preparation Platforms: Specializes in the delivery and development of drugs for the respiratory tract and topical applications.
- Polypeptide and Molecular Design Platform: Engages in the design and development of polypeptide drugs and other molecular entities.
- Genotoxic Impurity Detection: Offers a platform specifically for the detection of genotoxic impurities in pharmaceuticals.
- Technology Platform for Slow and Controlled Release: Focuses on the development of technologies for slow and controlled release pharmaceutical preparations.
- Drug Synthesis and Technology Platforms: Provides comprehensive support for the synthesis of drugs and the development of synthesis technologies.
- Service Offerings: Includes a wide range of services from SMO, clinical quality management, data management and statistical analysis, to project management, clinical trials, TMF document management, quality control, medical writing, medical monitoring, and pharmacovigilance services. Also provides registration-related services for chemical drugs, biological products, and medical devices.
- Quantitative Pharmacology Platform: Utilizes technology in pharmacokinetics, pharmacodynamics, and other areas for quantitative research into body functions and disease mechanisms.
- Biological Analysis Platforms: Comprises mass spectrometry, immunological analysis, cell biology, and molecular biology platforms for biological analysis services supporting both large and small molecular drugs.
- Contract Research Organizational Services: Offers specialized contract research organization (CRO) services for professional peptide drug research and development.
Contact Information
Address: Building 7, Beijing, China, 102200
Phone: 86 10 6074 8199
Website: https://www.sun-novo.com
